U.S., Jan. 28 -- ClinicalTrials.gov registry received information related to the study (NCT07369024) titled 'Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults' on Jan. 23.
Brief Summary: The purpose of this research is to see if ketamine is effective and safe in treating children and young adults with sickle cell disease experiencing sickle cell related pain. In this study, we will compare the outcomes (such as pain scores) in persons who receive standard of care pain medicine (an opioid such as morphine) plus a low dose (amount) of ketamine to those who receive only standard of care pain medicine.
Study Start Date: Jan., 2026
Study Type: INTERVENTIONAL
Condition:
Sickle Cell Disease...